Macrogol 4000 shortage — IT supply status & alternatives

Macrogol 4000

—

🇦🇺 AUST R 406341 · Aspen Pharmacare Australia Pty Ltd

In supply · Australia

Casenjunior

In supply · 🇦🇺 Australia · short in🇮🇹 IT

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Macrogol 4000
Brand names	Casenjunior
Therapeutic category	Auto-created by Agenzia Italiana del Farmaco — Carenze scraper

Marketing-authorisation holders	Aspen Pharmacare Australia Pty Ltd

Registrations on file	1

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Verified timeline regulator events

🇮🇹 18 June 2026

medium reported

🇮🇹 15 May 2026

Shortage resolved

🇮🇹 17 Nov 2025

medium reported

🇮🇹 30 May 2025

Shortage resolved

🇮🇹 31 Mar 2022

Shortage resolved

🇮🇹 1 Feb 2022

medium reported

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders1 registration · 1 MA holder

Product	Strength	Form	Market	MA holder	Status
COLOXYL MACROGOL FOR CHILDREN macrogol 4000	4g	—	🇦🇺 AU	Aspen Pharmacare Australia Pty Ltd	Active

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.